BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 167 products for "BTK".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Color and Shape:Odour SolidNRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Color and Shape:SolidMolecular weight:817.94BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Color and Shape:SolidMolecular weight:527.508TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Color and Shape:Odour SolidQL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Formula:C25H20ClN5O2Purity:99.25%Color and Shape:SolidMolecular weight:457.91IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Formula:C22H23ClN6OColor and Shape:SolidMolecular weight:422.91Zanubrutinib-D5
Zanubrutinib-d5 (BGB-3111-d5) is a deuterium-labeled Zanubrutinib, an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.Formula:C27H29N5O3Purity:>99.99%Color and Shape:White SolidMolecular weight:476.58Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Formula:C17H19N3O2Purity:99.77%Color and Shape:White SolidMolecular weight:297.36Ref: TM-T39130
1mg145.00€5mg250.00€10mg340.00€1mL*10mM (DMSO)356.00€25mg573.00€50mg879.00€100mg1,314.00€NX-5948
CAS:NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.Formula:C42H54N12O5Purity:98.29%Color and Shape:SolidMolecular weight:806.96Ref: TM-T75124
1mg80.00€5mg145.00€1mL*10mM (DMSO)178.00€10mg212.00€25mg339.00€50mg510.00€100mg708.00€N-piperidine Ibrutinib hydrochloride
CAS:N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.Formula:C22H23ClN6OPurity:98.83%Color and Shape:SolidMolecular weight:422.91Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Formula:C26H26N6O3Purity:99.98%Color and Shape:Yellow SolidMolecular weight:470.52Ref: TM-T4413
2mg34.00€5mg49.00€1mL*10mM (DMSO)50.00€10mg75.00€25mg146.00€50mg260.00€100mg409.00€200mg590.00€Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Color and Shape:Odour LiquidGDC-0834
CAS:GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse andFormula:C33H36N6O3SColor and Shape:SolidMolecular weight:596.74Larotinib mesylate hydrate
CAS:Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nMFormula:C26H36ClFN4O11S2Color and Shape:SolidMolecular weight:699.17Tuxobertinib
CAS:Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.Formula:C29H29ClN6O4Purity:99.22%Color and Shape:SolidMolecular weight:561.03Ref: TM-T9072
2mg38.00€5mg57.00€1mL*10mM (DMSO)71.00€10mg90.00€25mg178.00€50mg334.00€100mg497.00€200mg712.00€Olmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Formula:C26H26N6O2SPurity:99.14% - 99.63%Color and Shape:SolidMolecular weight:486.59Ref: TM-T6918
2mg37.00€5mg54.00€1mL*10mM (DMSO)56.00€10mg84.00€25mg130.00€50mg170.00€100mg268.00€200mg437.00€BMS-986142
CAS:BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).Formula:C32H30F2N4O4Purity:99.44% - 99.76%Color and Shape:SolidMolecular weight:572.6Ref: TM-T5138
1mg105.00€2mg165.00€5mg289.00€1mL*10mM (DMSO)358.00€10mg447.00€25mg715.00€50mg964.00€100mg1,243.00€200mg1,693.00€(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Formula:C11H8Br2N2O2Purity:99.88%Color and Shape:SolidMolecular weight:360Ibrutinib deacryloylpiperidine
CAS:Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.Formula:C17H13N5OPurity:99.47%Color and Shape:SolidMolecular weight:303.32
